To investigate the pharmacokinetics of oxycodone in perioperative liver cancer patients with normal liver function to support individualized analgesia.
Key Findings:
Oxycodone showed reduced clearance and prolonged half-life in liver cancer patients compared to healthy volunteers.
Increased volume of distribution and elevated exposure of oxycodone were observed.
Noroxycodone exhibited a biphasic profile with higher concentrations in males.
Significant sex-related differences were noted in oxycodone's area under the plasma concentration-time curve (AUC) and mean residence time (MRT).
Interpretation:
Remove unsupported conclusions about tailored analgesic strategies.
Limitations:
The study involved a small sample size of only nine patients.
Findings may not be generalizable to all liver cancer patients or those with impaired liver function.
Conclusion:
Remove unsupported claims about dose adjustments and monitoring.
